CN101959405B - 治疗糖尿病的氧杂二氮杂蒽化合物 - Google Patents
治疗糖尿病的氧杂二氮杂蒽化合物 Download PDFInfo
- Publication number
- CN101959405B CN101959405B CN200980108115.XA CN200980108115A CN101959405B CN 101959405 B CN101959405 B CN 101959405B CN 200980108115 A CN200980108115 A CN 200980108115A CN 101959405 B CN101959405 B CN 101959405B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- hydrogen
- oxo
- chloro
- anthracene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)OC(N(C1)[C@]2Cc(cc3N4)c1cc3OC(c(cc1)ccc1OCc(cc1)cc(Cl)c1Cl)C4=O)=*([C@@](Cc(cc1)ccc1-c(cc1)ccc1C#N)C(O)=O)C2=O Chemical compound CC(C)OC(N(C1)[C@]2Cc(cc3N4)c1cc3OC(c(cc1)ccc1OCc(cc1)cc(Cl)c1Cl)C4=O)=*([C@@](Cc(cc1)ccc1-c(cc1)ccc1C#N)C(O)=O)C2=O 0.000 description 5
- OAURIXDOYOTCSJ-KFAUHABRSA-N COC([C@H](Cc(cc1)ccc1-c(cc1)ccc1C#N)NC([C@H](Cc1c2)NCc1cc(OC1c(cc3)ccc3OCc(cc3Cl)ccc3Cl)c2NC1=O)=O)=O Chemical compound COC([C@H](Cc(cc1)ccc1-c(cc1)ccc1C#N)NC([C@H](Cc1c2)NCc1cc(OC1c(cc3)ccc3OCc(cc3Cl)ccc3Cl)c2NC1=O)=O)=O OAURIXDOYOTCSJ-KFAUHABRSA-N 0.000 description 1
- QUIJNNGHGSQUNF-FTSYTSSGSA-N COc(cc1)ccc1C(N(Cc(cc1OC2c(cc3)ccc3OCc(cc3)cc(Cl)c3Cl)c(C3)cc1NC2=O)[C@@H]3C(N[C@@H](Cc(cc1)ccc1-c(cc1)ccc1C#N)C(O)=O)=O)=O Chemical compound COc(cc1)ccc1C(N(Cc(cc1OC2c(cc3)ccc3OCc(cc3)cc(Cl)c3Cl)c(C3)cc1NC2=O)[C@@H]3C(N[C@@H](Cc(cc1)ccc1-c(cc1)ccc1C#N)C(O)=O)=O)=O QUIJNNGHGSQUNF-FTSYTSSGSA-N 0.000 description 1
- AVHHXIZSBMFBFP-FWGBPZCISA-N Cc1nc(CN(Cc(c(C2)c3)cc(OC4c(cc5)ccc5OCc(cc5Cl)ccc5Cl)c3NC4=O)[C@@H]2C(N[C@@H](Cc(cc2)ccc2-c(cc2)ccc2C#N)COCO)=O)ccc1 Chemical compound Cc1nc(CN(Cc(c(C2)c3)cc(OC4c(cc5)ccc5OCc(cc5Cl)ccc5Cl)c3NC4=O)[C@@H]2C(N[C@@H](Cc(cc2)ccc2-c(cc2)ccc2C#N)COCO)=O)ccc1 AVHHXIZSBMFBFP-FWGBPZCISA-N 0.000 description 1
- ZRLAMGNDDVCLCD-SYVAAPJHSA-N N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc2c3)N(Cc(cccc4)c4Cl)Cc2cc(OC2c(cc4)ccc4OCc(cc4Cl)ccc4Cl)c3NC2=O)=O)cc1 Chemical compound N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc2c3)N(Cc(cccc4)c4Cl)Cc2cc(OC2c(cc4)ccc4OCc(cc4Cl)ccc4Cl)c3NC2=O)=O)cc1 ZRLAMGNDDVCLCD-SYVAAPJHSA-N 0.000 description 1
- DQUXKPZGBXDRAB-SVDPPGBOSA-N N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc2c3)N(Cc4ncc[s]4)Cc2cc(OC2c(cc4)ccc4OCc4cccc(Cl)c4)c3NC2=O)=O)cc1 Chemical compound N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC(C(Cc2c3)N(Cc4ncc[s]4)Cc2cc(OC2c(cc4)ccc4OCc4cccc(Cl)c4)c3NC2=O)=O)cc1 DQUXKPZGBXDRAB-SVDPPGBOSA-N 0.000 description 1
- PRKJWSUINNVJIG-ALDZVHLRSA-N N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC([C@H](Cc(c(C2)c3)cc(N4)c3OC(c(cc3)ccc3OCc(cc3)cc(Cl)c3Cl)C4=O)N2C(N2CCCCC2)=O)=O)cc1 Chemical compound N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC([C@H](Cc(c(C2)c3)cc(N4)c3OC(c(cc3)ccc3OCc(cc3)cc(Cl)c3Cl)C4=O)N2C(N2CCCCC2)=O)=O)cc1 PRKJWSUINNVJIG-ALDZVHLRSA-N 0.000 description 1
- OJDOHMPBJTYOOR-PFYITYDVSA-N N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC([C@H](Cc(c(C2)c3)cc(N4)c3OC(c(cc3)ccc3OCc(cc3)cc(Cl)c3Cl)C4=O)N2C(c(c(F)cc(F)c2)c2F)=O)=O)cc1 Chemical compound N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC([C@H](Cc(c(C2)c3)cc(N4)c3OC(c(cc3)ccc3OCc(cc3)cc(Cl)c3Cl)C4=O)N2C(c(c(F)cc(F)c2)c2F)=O)=O)cc1 OJDOHMPBJTYOOR-PFYITYDVSA-N 0.000 description 1
- ZKQGQYVAMWKLIU-FTSYTSSGSA-N N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC([C@H](Cc2c3)N(Cc4ccccc4)Cc2cc(OC2c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c3NC2=O)=O)cc1 Chemical compound N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC([C@H](Cc2c3)N(Cc4ccccc4)Cc2cc(OC2c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c3NC2=O)=O)cc1 ZKQGQYVAMWKLIU-FTSYTSSGSA-N 0.000 description 1
- FPBZVDNUFCQOSU-FTSYTSSGSA-N N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC([C@H](Cc2c3)N(Cc4ccccc4F)Cc2cc(OC2c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c3NC2=O)=O)cc1 Chemical compound N#Cc(cc1)ccc1-c1ccc(C[C@@H](C(O)=O)NC([C@H](Cc2c3)N(Cc4ccccc4F)Cc2cc(OC2c(cc4)ccc4OCc(cc4)cc(Cl)c4Cl)c3NC2=O)=O)cc1 FPBZVDNUFCQOSU-FTSYTSSGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3459908P | 2008-03-07 | 2008-03-07 | |
| US61/034,599 | 2008-03-07 | ||
| PCT/US2009/036333 WO2009111700A2 (en) | 2008-03-07 | 2009-03-06 | Oxadiazoanthracene compounds for the treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101959405A CN101959405A (zh) | 2011-01-26 |
| CN101959405B true CN101959405B (zh) | 2014-07-02 |
Family
ID=41056666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980108115.XA Active CN101959405B (zh) | 2008-03-07 | 2009-03-06 | 治疗糖尿病的氧杂二氮杂蒽化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US7727983B2 (https=) |
| EP (1) | EP2262364B1 (https=) |
| JP (1) | JP5382952B2 (https=) |
| KR (1) | KR101616737B1 (https=) |
| CN (1) | CN101959405B (https=) |
| AU (1) | AU2009221722B2 (https=) |
| BR (1) | BRPI0910282A2 (https=) |
| CA (1) | CA2716664C (https=) |
| DK (1) | DK2262364T3 (https=) |
| EA (1) | EA018225B1 (https=) |
| ES (1) | ES2567451T3 (https=) |
| IL (1) | IL207570A (https=) |
| MA (1) | MA32175B1 (https=) |
| MX (1) | MX2010009752A (https=) |
| NZ (1) | NZ587343A (https=) |
| WO (1) | WO2009111700A2 (https=) |
| ZA (1) | ZA201006367B (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7727983B2 (en) | 2008-03-07 | 2010-06-01 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| JP5755217B2 (ja) * | 2009-03-30 | 2015-07-29 | トランステック・ファーマ，エルエルシー | 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| MX2013006768A (es) | 2010-12-23 | 2013-07-22 | Pfizer | Moduladores de receptor de glucagon. |
| WO2012096824A1 (en) | 2011-01-12 | 2012-07-19 | Transtech Pharma, Inc. | Phenylglyoxylic acid derivatives and their preparation and use |
| HRP20161177T1 (hr) | 2011-02-08 | 2016-11-04 | Pfizer Inc. | Modulator glukagonskog receptora |
| AU2012288493B2 (en) | 2011-07-22 | 2015-08-06 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EA201491749A1 (ru) * | 2012-03-22 | 2015-01-30 | ТРАНСТЕК ФАРМА, ЭлЭлСи | Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение |
| WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
| SG10201704716XA (en) * | 2013-01-17 | 2017-07-28 | Vtv Therapeutics Llc | Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders |
| EP3172199B1 (en) * | 2014-07-25 | 2020-07-01 | Celgene International II Sarl | Pyrimidine derivatives as glp-1 receptor modulators |
| US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| WO2019103060A1 (ja) * | 2017-11-22 | 2019-05-31 | 第一三共株式会社 | 縮合三環化合物 |
| EP3790549A1 (en) | 2018-05-08 | 2021-03-17 | vTv Therapeutics LLC | Therapeutic uses of glp1r agonists |
| CR20210341A (es) | 2018-11-22 | 2021-11-25 | Qilu Regor Therapeutics Inc | Agonistas de glp-ir y usos de los mismos |
| AU2020256647B2 (en) * | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| CA3157525A1 (en) | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US12459954B2 (en) | 2020-04-01 | 2025-11-04 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Crystalline form a of GLP-1 receptor agonist and preparation method therefor |
| WO2021196951A1 (zh) | 2020-04-01 | 2021-10-07 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| US20230348484A1 (en) * | 2020-05-28 | 2023-11-02 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Method for preparing glp-1 receptor agonist free base |
| EP4159719A4 (en) * | 2020-05-28 | 2024-07-17 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt |
| AU2021306414B2 (en) | 2020-09-01 | 2026-01-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| EP4227299A4 (en) | 2020-10-12 | 2025-04-09 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | GLP-1 RECEPTOR AGONIST, BENZIMIDAZOLONE AND ITS USE |
| TWI912388B (zh) * | 2020-10-14 | 2026-01-21 | 大陸商上海齊魯銳格醫藥研發有限公司 | Ｇｌｐ-１ｒ促效劑的晶型及其用途 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| US20240246959A1 (en) | 2020-11-27 | 2024-07-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Benzimidazole derivative and preparation method therefor and medical use thereof |
| CN116940561A (zh) | 2021-03-22 | 2023-10-24 | 杭州中美华东制药有限公司 | 噻吩类glp-1受体激动剂及其用途 |
| WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| PH12023552860A1 (en) | 2021-04-21 | 2024-05-20 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| WO2022262615A1 (zh) * | 2021-06-17 | 2022-12-22 | 杭州中美华东制药有限公司 | 蒽类化合物、其制备方法和医药用途 |
| WO2022268152A1 (zh) | 2021-06-24 | 2022-12-29 | 杭州中美华东制药有限公司 | Glp-1受体激动剂及其组合物和用途 |
| CN115521320B (zh) * | 2021-06-25 | 2023-09-05 | 沈阳兴齐眼药股份有限公司 | 一种制备普拉洛芬的方法 |
| US20260097037A1 (en) | 2022-09-22 | 2026-04-09 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| TW202521533A (zh) | 2023-09-14 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6345270A (ja) * | 1986-02-11 | 1988-02-26 | Takeda Chem Ind Ltd | １，４−ベンゾオキサジン誘導体，その製造法およびそれを含有する医薬用組成物 |
| EP0233728A1 (en) * | 1986-02-11 | 1987-08-26 | Takeda Chemical Industries, Ltd. | 1,4-Benzoxazine derivatives their production and use |
| CA2233888A1 (en) * | 1995-10-06 | 1997-04-10 | Ligand Pharmaceuticals Incorporated | Dimer-selective rxr modulators and methods for their use |
| JP2002534512A (ja) * | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドｇｌｐ−１アゴニスト |
| EP1236719A4 (en) * | 1999-12-03 | 2003-06-25 | Kyoto Pharma Ind | NOVEL HETEROCYCLIC COMPOUNDS AND SALTS THEREOF, USE OF THESE COMPOUNDS IN MEDICINE |
| EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| US20050222036A1 (en) | 2000-08-24 | 2005-10-06 | Thomas Jefferson University | Peptide compositions with effects on blood glucose |
| MXPA05010137A (es) * | 2003-03-26 | 2005-11-16 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina. |
| US7727983B2 (en) * | 2008-03-07 | 2010-06-01 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| US8501982B2 (en) | 2010-06-09 | 2013-08-06 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
-
2009
- 2009-03-06 US US12/399,504 patent/US7727983B2/en active Active
- 2009-03-06 CN CN200980108115.XA patent/CN101959405B/zh active Active
- 2009-03-06 KR KR1020107020688A patent/KR101616737B1/ko not_active Expired - Fee Related
- 2009-03-06 JP JP2010549910A patent/JP5382952B2/ja active Active
- 2009-03-06 DK DK09718287.7T patent/DK2262364T3/en active
- 2009-03-06 ES ES09718287T patent/ES2567451T3/es active Active
- 2009-03-06 BR BRPI0910282-5A patent/BRPI0910282A2/pt not_active Application Discontinuation
- 2009-03-06 CA CA2716664A patent/CA2716664C/en active Active
- 2009-03-06 NZ NZ587343A patent/NZ587343A/en not_active IP Right Cessation
- 2009-03-06 WO PCT/US2009/036333 patent/WO2009111700A2/en not_active Ceased
- 2009-03-06 EA EA201071045A patent/EA018225B1/ru not_active IP Right Cessation
- 2009-03-06 MX MX2010009752A patent/MX2010009752A/es active IP Right Grant
- 2009-03-06 EP EP09718287.7A patent/EP2262364B1/en active Active
- 2009-03-06 AU AU2009221722A patent/AU2009221722B2/en active Active
-
2010
- 2010-04-13 US US12/759,010 patent/US7790714B2/en active Active
- 2010-08-03 US US12/849,225 patent/US7906507B2/en active Active
- 2010-08-12 IL IL207570A patent/IL207570A/en active IP Right Grant
- 2010-08-31 US US12/872,580 patent/US8524708B2/en not_active Expired - Fee Related
- 2010-09-10 ZA ZA2010/06367A patent/ZA201006367B/en unknown
- 2010-09-30 MA MA33212A patent/MA32175B1/fr unknown
-
2013
- 2013-08-01 US US13/956,578 patent/US8703766B2/en not_active Expired - Fee Related
-
2014
- 2014-03-05 US US14/197,771 patent/US8933222B2/en active Active
- 2014-12-01 US US14/556,837 patent/US9120813B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101959405B (zh) | 治疗糖尿病的氧杂二氮杂蒽化合物 | |
| CN102378574B (zh) | 取代的偶氮蒽衍生物、药物组合物及其使用方法 | |
| CN100413849C (zh) | 苯并咪唑衍生物 | |
| US10669239B2 (en) | Tetrahydronaphthyl urea derivative | |
| JP2015051992A (ja) | アミノオキサジン誘導体 | |
| WO2024146632A1 (zh) | 一种四氢噻吩衍生物及其在医药上的应用 | |
| HK1148435B (en) | Oxadiazoanthracene compounds for the treatment of diabetes | |
| AU2003289904A1 (en) | Substituted benzodioxepins | |
| HK40085148B (zh) | 杂环glp-1激动剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1148435 Country of ref document: HK |
|
| ASS | Succession or assignment of patent right |
Owner name: TRANSFORMATION TECHNOLOGY PHARMA, LLC Free format text: FORMER OWNER: TRANSTECH PHARMA INC. Effective date: 20140328 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20140328 Address after: North Carolina Applicant after: TRANSTECH PHARMA, Inc. Address before: North Carolina Applicant before: Transtech Pharma, Inc. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1148435 Country of ref document: HK |
|
| C56 | Change in the name or address of the patentee |
Owner name: VTV THERAPEUTICS LLC Free format text: FORMER NAME: TRANSFORMATION TECHNOLOGY PHARMA, LLC |
|
| CP01 | Change in the name or title of a patent holder |
Address after: North Carolina Patentee after: vTv Therapeutics LLC Address before: North Carolina Patentee before: TRANSTECH PHARMA, Inc. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: North Carolina Patentee after: VTVX Holdings I LLC Address before: North Carolina Patentee before: VTV THERAPEUTICS LLC |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20151130 Address after: North Carolina Patentee after: vTv Therapeutics LLC Address before: North Carolina Patentee before: VTVX Holdings I LLC |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20110126 Assignee: HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL Co.,Ltd. Assignor: VTV THERAPEUTICS LLC Contract record no.: 2018990000060 Denomination of invention: Oxadiazoanthracene compounds for the treatment of diabetes Granted publication date: 20140702 License type: Exclusive License Record date: 20180313 |
|
| EE01 | Entry into force of recordation of patent licensing contract |